New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 3, 2010, Pages 186-193

  Lienhardt, Christian ^a   Vernon, Andrew ^b   Raviglione, Mario C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Drug development; Drug resistant tuberculosis; Drug susceptible tuberculosis; Multidrug therapy

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; UNINDEXED DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DYSGLYCEMIA; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; REVIEW; SIDE EFFECT; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; FORECASTING; HUMANS; MALE; NITROIMIDAZOLES; RIFAMYCINS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 77951092627     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328337580c     Document Type: Review

References (74)

1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986. Int J Tuberc Lung Dis 1999; 3:S231-S279.
2. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008; 336:484-487.
3. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477.
4. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364:1244-1251.
5. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and metaanalysis. PLoS Med 2009; 6:e1000146.
6. WHO. Treatment of tuberculosis: guidelines, 4th ed. [WHO/HTM/TB/ 2009.420]. Geneva, Switzerland: World Health Organization; 2009.
7. World Health Organization. Treatment of tuberculosis: guidelines for national programmes WHO/CDS/TB/2008 (revised); June 2008. 108 p.
8. Mak A, Thomas A, Granado M, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178:306-312.
9. Espinal M, Raviglione MC. From threat to reality: the real face of multidrugresistant tuberculosis. Am J Respir Crit Care Med 2008; 178:216-217.
10. Kimerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO retreatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999; 3:451-453.
11. Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4:108-114.
12. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000150.
13. World Health Organization. Stop TB Dept. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency Update 2008 [WHO/ HTM/TB/2008.402]. Geneva, Switzerland: World Health Organization; 2008.
14. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33:1085-1094.
15. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-161.
16. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4:e6914.
17. OÕDonnell MR, Padayatchi N, Master I, et al. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 2009; 13:855-861.
18. World Health Organization. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis [WHA62.15]. 62nd World Health Assembly; 22 May 2009.
19. Lawn SD, Gail-Bekker L, Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
20. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIVinfected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196 (Suppl 1):S46-S51.
21. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva, Switzerland: WHO; November 2009.
22. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIVinfected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
23. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resourcelimited settings. Lancet Infect Dis 2008; 8:516-523.
24. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicinbased antitubercular therapy. JAMA 2008; 300:530-539.
25. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752-1759.
26. LÕhomme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 27:863-865.
27. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49:1305-1311.
28. Khachi H, OÕConnell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009; 64:871-873.
29. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979; 119:827-830.
30. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60:555-564.
31. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000:CD001363.
32. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a metaanalysis. Clin Infect Dis 2005; 40:670-676.
33. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45:715-722.
34. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149:689-697.
35. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49:1883-1889.
36. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2006:CD000171.
37. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 2008; 12:1352-1364.
38. Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51:2994-2996.
39. Keung AC, Owens RC Jr, Eller MG, et al. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Antimicrob Agents Chemother 1999; 43:1230-1233.
40. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353:1843-1847.
41. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drugsusceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360:528-534.
42. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentinecontaining regimens in murine tuberculosis. Am J Respir Crit Care Med 2008; 178:989-993.
43. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4:e344.
44. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2:265-271.
45. Moadebi S, Harder CK, Fitzgerald MJ, et al. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67:2077-2099.
46. Rodriguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17:229-231.
47. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacteriumtuberculosis. Int J Antimicrob Agents 2002; 20:464-467.
48. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-657.
49. Sulochana S, Rahman F, Paramasivan CN. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005; 17:169-173.
50. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12:128-138.
51. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373:1183-1189.
52. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331-338.
53. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-280. [50] and Rio [51] studies, these two trials were multicenter trials and did not standardize laboratory methods.
54. Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007; 13:290-294.
55. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-227.
56. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC-207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:2831-2835.
57. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-2405.
58. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962-966.
59. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322: 1392-1395.
60. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3:e466
61. Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009; 53:3720-3725.
62. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358:1975-1982.
63. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008; 178:1180-1185.
64. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34:387-393.
65. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrugresistant tuberculosis. Clin Infect Dis 2010; 50:49-55.
66. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64:388-391.
67. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43:1189-1191.
68. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53:1314-1319.
69. Williams KN, Brickner SJ, Stover CK, et al. Addition of PNU-100480 to firstline drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009; 180:371-376.
70. Lee RE, Protopopova M, Crooks E, et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 2003; 5:172-187.
71. Nikonenko BV, Protopopova M, Samala R, et al. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51: 1563-1565.
72. Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb) 2008; 88 (Suppl 1):S3-S17.
73. Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb) 2008; 88 (Suppl 1):S85-S92.
74. Sacks LV, Behrman RE. Developing new drugs for the treatment of drugresistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb) 2008; 88 (Suppl 1):S93-S100.